Stockscreener 앱 받기
7.21
0.41%
-0.04
시간 외 거래:
7.22
0.010
+0.14%
전일 마감가:
$7.25
열려 있는:
$7.255
하루 거래량:
2.92M
Relative Volume:
0.97
시가총액:
$1.51B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-40.06
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
+0.98%
1개월 성능:
-9.86%
6개월 성능:
+12.64%
1년 성능:
+1.40%
1일 변동 폭
$7.08
$7.32
1주일 범위
$6.935
$7.335
52주 변동 폭
$6.015
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.21 | 1.52B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
141.09 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
439.99 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
How high can BioCryst Pharmaceuticals Inc. stock goAnalyst Downgrade & Fast Entry High Yield Stock Tips - newser.com
Multi factor analysis applied to BioCryst Pharmaceuticals Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com
Has BioCryst Pharmaceuticals Inc. formed a bullish divergenceTrade Analysis Report & Risk Managed Investment Signals - newser.com
How BioCryst Pharmaceuticals Inc. stock reacts to oil pricesAnalyst Upgrade & Proven Capital Preservation Tips - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX) - The Globe and Mail
Is BioCryst Pharmaceuticals Inc. stock poised for growthJuly 2025 Patterns & Stock Portfolio Risk Management - newser.com
BioCryst Pharma Nears Defining FDA Moment For Pediatric HAE Therapy - RTTNews
Quantitative breakdown of BioCryst Pharmaceuticals Inc. recent moveDip Buying & Low Drawdown Trading Techniques - newser.com
RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating - MarketScreener
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Zacks Research - MarketBeat
BioCryst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround - Yahoo Finance
Custom strategy builders for tracking BioCryst Pharmaceuticals Inc.Weekly Trade Summary & Technical Pattern Based Signals - newser.com
BioCryst Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Applying chart zones and confluence areas to BioCryst Pharmaceuticals Inc.July 2025 Short Interest & Technical Entry and Exit Tips - newser.com
BioCryst Pharmaceuticals (BCRX): Exploring Valuation After Recent Share Price Drift - Sahm
Will earnings trigger a reversal in BioCryst Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com
BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market - Insider Monkey
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
How to monitor BioCryst Pharmaceuticals Inc. with trend dashboardsQuarterly Profit Review & Low Risk Entry Point Guides - newser.com
BioCryst (BCRX) Grants Stock Options and RSUs to New Employees - GuruFocus
Is BioCryst Pharmaceuticals Inc. showing signs of accumulationQuarterly Market Summary & Verified Momentum Watchlists - newser.com
115,000 Options & 91,450 RSUs — BioCryst Grants Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
BioCryst Pharmaceuticals Enters Oversold Territory (BCRX) - Nasdaq
Biocryst sells European rights to HAE therapy Orladeyo for $250M - Angioedema News
BioCryst Sells European ORLADEYO Business for $250M - The Globe and Mail
10 Best Stocks to Buy Under $20 - Insider Monkey
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.2%Here's Why - MarketBeat
Neopharmed Gentili completes acquisition of the European ORLADEYO® business from BioCryst Pharmaceuticals - firstonline.info
Top chart patterns to watch in BioCryst Pharmaceuticals Inc.Market Risk Report & Reliable Intraday Trade Alerts - newser.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "In-Line" Rating at Evercore ISI - MarketBeat
BioCryst (BCRX) Finalizes European ORLADEYO Business Sale - GuruFocus
BioCryst Pharmaceuticals Closes $250 Million Sale of Orladeyo Business in Europe - MarketScreener
Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12 - MarketScreener
BioCryst completes $250 million sale of European ORLADEYO business By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
BioCryst completes $250 million sale of European ORLADEYO business - Investing.com
Biocryst completes sale of European Orladeyo (berotralstat) business - MarketScreener
BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili - Quiver Quantitative
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business - GlobeNewswire
$250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus - Stock Titan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오크리스트 주식 (BCRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director |
Aug 13 '25 |
Sale |
8.51 |
70,000 |
595,868 |
65,352 |
1.54%
1.16%
자본화:
|
볼륨(24시간):